Achieving high immunogenicity against poliovirus with fractional doses of inactivated poliovirus vaccine in Ecuador-results from a cross-sectional serological survey

Trueba, Gabriel; Jeyaseelan, Vishali; López, Lázaro; Mainou, Bernardo A.; Yiting, Zhang; Whittembury, Álvaro; Valarezo, Alfredo Jose Olmedo; Baquero, Gonzalo; Aguinaga, Rosa Romero de; Salinas, Lucia Jeannete Zurita; Mancheno, Maria Gabriela Santacruz; Chacho, Diana Elizabeth Medina; Quentin, Emmanuelle; Chévez, Ana Elena; Rey-Benito, Gloria; Mach, Ondrej

doi:10.1016/j.lana.2022.100235

Cited by 5 publications

(2 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are six countries that currently use off-label fIPV administered intradermally in their RI schedules, namely Bangladesh, Cuba, Ecuador, India, Sri Lanka, and Nepal. Serological assessments from Cuba, Ecuador and India demonstrated high immunogenicity of their fIPV immunization schedules [ 29 , 31 , 32 ].…”

Section: Closing In On Poliovirus Eradicationmentioning

confidence: 99%

The Last Mile in Polio Eradication: Program Challenges and Perseverance

Lopez Cavestany,

Eisenhawer,

Diop

et al. 2024

Pathogens

Self Cite

View full text Add to dashboard Cite

As the Global Polio Eradication Initiative (GPEI) strategizes towards the final steps of eradication, routine immunization schedules evolve, and high-quality vaccination campaigns and surveillance systems remain essential. New tools are consistently being developed, such as the novel oral poliovirus vaccine to combat outbreaks more sustainably, as well as non-infectiously manufactured vaccines such as virus-like particle vaccines to eliminate the risk of resurgence of polio on the eve of a polio-free world. As the GPEI inches towards eradication, re-strategizing in the face of evolving challenges and preparing for unknown risks in the post-certification era are critical.

show abstract

Section: Closing In On Poliovirus Eradicationmentioning

confidence: 99%

The Last Mile in Polio Eradication: Program Challenges and Perseverance

Lopez Cavestany,

Eisenhawer,

Diop

et al. 2024

Pathogens

Self Cite

View full text Add to dashboard Cite

show abstract

“…Our work focused on the reduction in number of IPV doses and on its potency (i.e., fIPV), and was building on the studies conducted earlier in India [ 50 , 51 ]. Many follow-up studies were conducted in subjects that had not received OPV, in Cuba [ 39 , 40 , 46 ], the Philippines [ 52 ], the Netherlands [ 53 ], Oman [ 41 ], Sri Lanka [ 35 ], The Gambia [ 54 ], Ecuador [ 55 ], India [ 56 ], Pakistan [ 42 , 44 ] and Bangladesh [ 24 , 36 , 38 , 57 , 58 ] with vaccines from several manufacturers (Staten Serum Institute, Denmark, Bilthoven Biologicals, the Netherlands, and Sanofi Pasteur, France). These studies demonstrated that two fractional IPV doses given at age 14–16 weeks and 8–9 months could induce high seroconversion rates (above 90%).…”

Section: Increasing the Scientific Knowledge Base Of Ipvmentioning

confidence: 99%

Inactivated Poliovirus Vaccine: Recent Developments and the Tortuous Path to Global Acceptance

Sutter,

Eisenhawer,

Molodecky

et al. 2024

Pathogens

View full text Add to dashboard Cite

Inactivated poliovirus vaccine (IPV), available since 1955, became the first vaccine to be used to protect against poliomyelitis. While the immunogenicity of IPV to prevent paralytic poliomyelitis continues to be irrefutable, its requirement for strong containment (due to large quantities of live virus used in the manufacturing process), perceived lack of ability to induce intestinal mucosal immunity, high cost and increased complexity to administer compared to oral polio vaccine (OPV), have limited its use in the global efforts to eradicate poliomyelitis. In order to harvest the full potential of IPV, a program of work has been carried out by the Global Polio Eradication Initiative (GPEI) over the past two decades that has focused on: (1) increasing the scientific knowledge base of IPV; (2) translating new insights and evidence into programmatic action; (3) expanding the IPV manufacturing infrastructure for global demand; and (4) continuing to pursue an ambitious research program to develop more immunogenic and safer-to-produce vaccines. While the knowledge base of IPV continues to expand, further research and product development are necessary to ensure that the program priorities are met (e.g., non-infectious production through virus-like particles, non-transmissible vaccine inducing humoral and intestinal mucosal immunity and new methods for house-to-house administration through micro-needle patches and jet injectors), the discussions have largely moved from whether to how to use this vaccine most effectively. In this review, we summarize recent developments on expanding the science base of IPV and provide insight into policy development and the expansion of IPV manufacturing and production, and finally we provide an update on the current priorities.

show abstract